Valuation: Atossa Therapeutics, Inc.

Market Cap 26.35M 22.58M 21.12M 19.31M 36.44M 2.52B 36.83M 250M 97.19M 1.27B 98.92M 96.78M 4.19B P/E 2026 *
-0.69x
P/E 2027 * -0.84x
Enterprise Value 26.35M 22.58M 21.12M 19.31M 36.44M 2.52B 36.83M 250M 97.19M 1.27B 98.92M 96.78M 4.19B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 week+1.35%
Current month+26.81%
1 month+11.23%
3 months-46.97%
6 months-38.52%
Current year-70.34%
1 week 2.44
Extreme 2.44
2.76
1 month 2.05
Extreme 2.05
2.97
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
64.65
10 years 1.7
Extreme 1.7
694.8
Manager TitleAgeSince
Chief Executive Officer 75 01/04/2009
Director of Finance/CFO 50 14/10/2025
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Chairman 75 01/04/2009
Director/Board Member 64 01/04/2009
Director/Board Member 79 01/07/2011
Date Insider Type Main position Quantity % Market Cap.
1/20/26 A Free

Chief Executive Officer

1,281,674 0.9922%
1/20/26 A
Ensisheim Partners LLC
OtherCompany 0 0%
10/14/25 A Free

Chief Financial Officer

578,000 0.4595%
Change 5-day change 1-year change 3-year change Capi.($)
-0.57%+1.35%-76.97%-79.44% 26.35M
+1.28%+5.34%+4.05%+25.92% 51.21B
+1.07%-0.62%+501.82%+547.77% 45.35B
-0.68%+8.27%+38.22%+18.66% 42.84B
+1.72%+2.26%+22.31%+90.26% 42.29B
-2.27%-5.67%+14.55%+50.34% 32.15B
-1.45%+3.69%+31.12%+135.58% 17.31B
+0.40%+1.51% - - 16.55B
+1.28%+6.55%+11.21%+32.87% 14.84B
-0.61%+6.43%+81.07%+48.29% 14.25B
Average +0.06%+2.21%+69.71%+96.70% 27.68B
Weighted average by Cap. +0.25%+2.89%+107.09%+138.03%

Financials

2026 *2027 *
Net sales - -
Net income -34.89M -29.9M -27.97M -25.58M -48.26M -3.34B -48.78M -331M -129M -1.68B -131M -128M -5.55B -38.03M -32.59M -30.49M -27.87M -52.6M -3.64B -53.16M -361M -140M -1.83B -143M -140M -6.05B
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
25/08/26 $2.625 -0.57% 19,269
24/08/26 $2.640 +3.94% 57,149
21/08/26 $2.540 -1.93% 25,656
20/08/26 $2.590 -1.89% 70,954
19/08/26 $2.640 +1.93% 62,197
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.640USD
Average target price
18.67USD
Spread / Average Target
+607.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock